Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Cash from Financing Activities (2016 - 2025)

Moleculin Biotech's Cash from Financing Activities history spans 10 years, with the latest figure at $7.5 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $7.5 million for Q4 2025, up 748600.0% from a year ago — trailing twelve months through Dec 2025 was $27.3 million (up 488.65% YoY), and the annual figure for FY2025 was $27.3 million, up 488.65%.
  • Cash from Financing Activities for Q4 2025 was $7.5 million at Moleculin Biotech, up from $6.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $74.7 million in Q1 2021 to a low of -$25000.0 in Q2 2024.
  • The 5-year median for Cash from Financing Activities is $141000.0 (2023), against an average of $7.4 million.
  • The sharpest move saw Cash from Financing Activities tumbled 151.02% in 2024, then surged 748600.0% in 2025.
  • Year by year, Cash from Financing Activities stood at -$24000.0 in 2021, then soared by 54.17% to -$11000.0 in 2022, then skyrocketed by 36054.55% to $4.0 million in 2023, then plummeted by 99.97% to $1000.0 in 2024, then surged by 748600.0% to $7.5 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $7.5 million, $6.4 million, and $5.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.